Menu

Image of the Day: Switch Gears

A gene responsible for the free-moving, primitive nature of fetal cells is expressed in some breast cancer cells in mice and humans.

Sep 10, 2018
Sukanya Charuchandra

ABOVE: Left panel: Considerable numbers of invasive cancer cells with Sox10 (red) in them can be found outside of mouse tumors in vivo (green cells, outlined). Right panel: The invasive cells are proximal to blood vessels (white).
SALK INSTITUTE/SANFORD CONSORTIUM FOR REGENERATIVE MEDICINE

Agene known to be active in fetal cells is also expressed in aggressive forms of breast cancer, pointing to a possible explanation for cancer cells’ ability to regain the potential to evolve into other types and metastasize to different regions in the body. The findings were published last month (August 30) in Cancer Cell.

The gene in question, Sox10, controls several processes, including cell development and movement, as a transcription factor.

The researchers noticed that breast cancer cells from humans and mice with abundant Sox10 reverted to undifferentiated variants that turned invasive and freely migrated. In a mouse experiment, they observed that disrupting Sox10 function stopped cancer formation in breast cells that had been primed to former tumors. 

C. Dravis et al., “Epigenetic and transcriptomic profiling of mammary gland development and tumor models disclose regulators of cell state plasticity,” Cancer Cell, doi:10.1016/j.ccell.2018.08.001, 2018.

Clarification (September 10): Upon request, we changed the credit for the image from Salk Institute to Salk Institute/Sanford Consortium for Regenerative Medicine. 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Preparing Cell Or Tissue Lysates For ELISA Kits

Preparing Cell Or Tissue Lysates For ELISA Kits

RayBiotech manufactures over 2,000 high fully validated, GMP-compliant ELISA kits. In this blog post we explain how to prepare cell or tissue lysates for ELISA Kits.

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider.

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.